> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# PTC Therapeutics Lifts 2026 Product Revenue Outlook To $960 Million-$990 Million After Sephience Sales Reach $181.9 Million
- URL: https://www.bullished.co/ptc-therapeutics-lifts-2026-product-revenue-outlook-to-960-million-990-million-after-109cb2aa/
- Published: 2026-10-29T20:27:57.000Z
- Updated: 2026-10-29T20:27:57.000Z
- Description: The rare-disease drugmaker posted a $51.7 million quarterly net loss after booking $111.0 million for a Fabry gene therapy it bought.
- Author: Matteo Parrino
- Tags: Earnings, PTCT, Industry: Healthcare

PTC Therapeutics, which develops and sells medicines for rare disorders, raised its 2026 product revenue guidance to [$960 million to $990 million](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926120200/tmb-ex99d1.htm?ref=bullished.co) from $850 million to $950 million, the company said Thursday in its third-quarter results. The same report showed a $51.7 million net loss, after a $111.0 million charge for buying a Fabry disease gene therapy.

## Product sales more than double

Net product revenue across the portfolio was $275.9 million in the third quarter, against $131.0 million a year earlier, an increase of more than 100%, the [company reported](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co). Including royalties, revenue was $357.6 million, compared with $201.7 million a year earlier. Total 2026 revenue is now expected at $1.29 billion to $1.32 billion.

Sephience, the company's drug for the metabolic disorder phenylketonuria (PKU), brought in $181.9 million, up 20% from the second quarter. The US supplied $145 million and markets outside it $37 million, and more than 2,000 patients were on therapy worldwide as of September 30\. Sephience revenue for the first nine months was $458 million, according to the company's [presentation](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926120200/tmb-ex99d2.htm?ref=bullished.co).

CEO Matthew B. Klein said the launch is "firmly on track to achieve our cash flow breakeven milestone this year."

## Older drugs shrink, loss widens

Translarna sales slipped to [$48.5 million](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co) from $50.7 million and included a purchase order from the Russian government. Emflaza fell to $25.1 million from $35.2 million. Royalties from Roche's Evrysdi added $81.7 million, against $70.8 million a year earlier.

The net loss compares with net income of $15.9 million a year earlier. Beyond the $111.0 million expense for ST-920, bought from Sangamo Therapeutics, the quarter carried a $19.3 million loss on extinguishing debt. Operating income was $25.1 million. Net interest expense was $45.9 million.

Cash and marketable securities stood at $2,127.9 million on September 30, against $1,945.4 million at the end of 2025\. Total debt rose to $536.3 million from $286.6 million.

## Fabry filing and Huntington's meeting

PTC paid $111.0 million upfront for ST-920, a one-time gene therapy for Fabry disease, with up to $100.0 million more tied to US approvals. It expects to finish its biologics license application in the fourth quarter, with possible accelerated approval and a launch in 2027.

An FDA meeting on votoplam, a Huntington's disease drug, is now set for the first quarter of 2027 because of FDA scheduling. The meeting will cover Phase 2 data and a possible accelerated approval path.

PTC's expense guidance is unchanged, at $775 million to $815 million on a standard-accounting basis for research and administrative costs combined.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — PTC THERAPEUTICS, INC. (PTCT)](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926120200/tmb-20261029x8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tmb-ex99d1.htm — PTC THERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926120200/tmb-ex99d1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tmb-ex99d2.htm — PTC THERAPEUTICS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001070081/000110465926120200/tmb-ex99d2.htm?ref=bullished.co) — SEC EDGAR
- [PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2026-financial-results-302924188.html?ref=bullished.co) — prnewswire.com